About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Gt(ROSA)26Sortm1(EYFP)Cos
targeted mutation 1, Frank Costantini
MGI:2449038
Summary 51 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Runx1tm2.1(cre/Esr1*)Ims/Runx1tm1Medv
B6.Cg-Gt(ROSA)26Sortm1(EYFP)Cos Runx1tm2.1(cre/Esr1*)Ims MGI:5316038
cn2
Ascl1tm1And/Ascl1tm1And
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Ascl1-EGFP,-cre)1Jejo/0
involves: 129 * 129X1/SvJ * C57BL/6 * DBA MGI:4420909
cn3
Nkx6-1tm1Jlr/Nkx6-1tm1.1Msan
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
involves: 129 * C57BL/6 * DBA * SJL MGI:5501188
cn4
Rbpjtm1Hon/Rbpjtm1.1Hon
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ptf1atm2(cre/ESR1)Cvw/Ptf1a+
involves: 129P2/OlaHsd * 129S1/Sv * 129S6/SvEvTac MGI:5310800
cn5
Rbpjtm1Hon/Rbpjtm1.1Hon
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hes1tm1(cre/ERT2)Lcm/Hes1+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:5310799
cn6
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N MGI:6377668
cn7
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N MGI:6377669
cn8
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N MGI:6377665
cn9
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N MGI:6377664
cn10
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N MGI:6377672
cn11
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N MGI:6377671
cn12
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N MGI:6360589
cn13
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
involves: 129P2/OlaHsd * 129X1/SvJ MGI:5762939
cn14
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lhx6tm2Vpa/Lhx6tm2Vpa
Tg(Nkx2-1-cre)1Wdr/0
involves: 129P2/OlaHsd * 129X1/SvJ MGI:5491493
cn15
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac MGI:5442608
cn16
Cdc42tm1Brak/Cdc42tm1Brak
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 MGI:5427870
cn17
Lcp2tm1Gak/Lcp2tm2Gak
Tg(VAV1-cre)1Graf/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ MGI:4843965
cn18
Syktm1.1(cre)Fkfr/Syktm1.1(cre)Fkfr
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
involves: 129S1/Sv * 129X1/SvJ MGI:4844099
cn19
Eedtm1Sho/Eedtm1Sho
Eportm1.1(EGFP/icre)Uk/Epor+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ MGI:4410547
cn20
Lcp2tm1Gak/Lcp2tm2Gak
Tg(Pf4-icre)Q3Rsko/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:4843964
cn21
Ednrbtm1Nrd/Ednrbtm1Nrd
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/J MGI:3814191
cn22
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ilktm1Star/Ilktm1Star
Tg(Krt1-15-cre/PGR*)22Cot/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J MGI:5009342
cn23
Fevtm1Esd/Fevtm2Esd
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Fev-cre)1Esd/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL MGI:4837213
cn24
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Corintm2(cre)Bamo/Corin+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * FVB/N MGI:4844104
cn25
Hoxb1tm1.1Mist/Hoxb1tm1.1Mist
Tg(Hoxb1-cre)r4Mist/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CD-1 MGI:5491188
cn26
Hoxb1tm1Mist/Hoxb1tm1Mist
Tg(Hoxb1-cre)r4Mist/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CD-1 MGI:5491185
cn27
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 MGI:5485201
cn28
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Tnnt2-cre)5Blh/0
involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * C57BL/6N * DBA/2 MGI:6360587
cn29
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
S1pr1tm2Rlp/S1pr1tm2Rlp
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129S6/SvEvTac * 129X1/SvJ MGI:5445987
cn30
Ctnnb1tm1Mmt/Ctnnb1+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Prom1tm1(cre/ERT2)Gilb/Prom1+
involves: 129S6/SvEvTac * 129X1/SvJ MGI:3830626
cn31
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
Pax7tm1(cre/ERT2)Gaka/Pax7tm1(cre/ERT2)Gaka
Paxbp1tm1.1Nju/Paxbp1tm1.1Nju
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6NCr MGI:6827448
cn32
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Resttm1.1Jhsi/Resttm1.1Jhsi
Tg(Nes-cre/ERT2)KEisc/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL MGI:5141116
cn33
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw
Rag2tm1Fwa/Rag2tm1Fwa
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S/SvEv * 129X1/SvJ * C57BL/6 MGI:5697630
cn34
Sh2d1atm1.1Knic/Sh2d1atm1.1Knic
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129X1/SvJ * C57BL/6 MGI:5502763
cn35
Sh2d1atm1.1Knic/Y
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129X1/SvJ * C57BL/6 MGI:5502766
cn36
Slc17a6tm1.1Thna/Slc17a6tm1.1Thna
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129/Sv * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J MGI:4879095
cn37
Bhlhe22tm3.1(cre)Meg/Bhlhe22tm1Meg
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129/Sv * 129X1/SvJ MGI:4440935
cn38
Cd79atm1(cre)Reth/Cd79a+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129X1/SvJ * BALB/c * C57BL/6 MGI:3687456
cn39
Gt(ROSA)26Sortm1Hjf/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(CMV-cre)1Cgn/0
involves: 129X1/SvJ * BALB/cJ * C57BL/6 MGI:3696483
cn40
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprttm1(Ins2-HBEGF)Herr/Y
Tg(Gcg-rtTA)#Herr/0
Tg(tetO-cre)1Jaw/0
involves: 129X1/SvJ * C57BL/6 MGI:5567830
cn41
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129X1/SvJ * C57BL/6 MGI:5697628
cn42
Amotl1tm1Laho/Amotl1tm1Laho
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129X1/SvJ * C57BL/6 MGI:6723729
cn43
Ctdnep1tm3Ryn/Ctdnep1tm3Ryn
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Six2tm1(tTA,tetO-EGFP/cre)Amc/Six2+
involves: 129X1/SvJ * C57BL/6 * C57BL/6J MGI:5548193
cn44
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprttm1(Ins2-HBEGF)Herr/Y
Tg(Ins2-cre/ERT)1Dam/0
involves: 129X1/SvJ * C57BL/6 * CBA MGI:5567828
cn45
Bcl11atm1Pwt/Bcl11atm1Pwt
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: 129X1/SvJ * C57BL/6 * CBA MGI:5564909
cn46
Gt(ROSA)26Sortm1(EYFP)Cos/?
Tg(Il17f-cre)1Awai/?
involves: 129X1/SvJ * C57BL/6 * DBA MGI:3831109
cn47
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Plcg1tm1Gcrp/Plcg1tm1Rwen
Tg(Cd4-cre)1Cwi/0
involves: 129X1/SvJ * C57BL/6 * DBA/2 MGI:4437914
cn48
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Il22tm1.1(icre)Stck/Il22+
involves: 129X1/SvJ * C57BL/6N MGI:5634193
cn49
Gt(ROSA)26Sortm1(EYFP)Cos/?
Tg(Lck-cre)548Jxm/0
involves: 129X1/SvJ * C57BL/6 * SJL MGI:3696478
cn50
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Plp1-Ncre)DFki/0
Tg(Plp1-Ccre)RFki/0
involves: 129X1/SvJ * FVB/N MGI:3835668
cn51
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(GFAP-Ccre)FFki/0
Tg(GFAP-Ncre)VFki/0
involves: 129X1/SvJ * FVB/N MGI:3835669


Genotype
MGI:5316038
cn1
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Runx1tm2.1(cre/Esr1*)Ims/Runx1tm1Medv
Genetic
Background
B6.Cg-Gt(ROSA)26Sortm1(EYFP)Cos Runx1tm2.1(cre/Esr1*)Ims
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Runx1tm1Medv mutation (0 available); any Runx1 mutation (25 available)
Runx1tm2.1(cre/Esr1*)Ims mutation (0 available); any Runx1 mutation (25 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• with maternal injection of high-dose tamoxifen on E7.5 to induce Runx1 reactivation, trasnsplanted, hematopoietic stem cells were isolated and injected into irradiated recipients for a long-term competitive repopulation assay; at E14.5 and E16.5, no signficant differences in reconstitution levels of hematopoietic cells is observed relative to controls
• secondary transplantation of yolk sac-derived bone marrow cells from the primary recipients 12 months following primary transplantation resulted in long-term engraftment
• exposure of embryos to tamoxifen at E10.5 fails to result in observation of CD45+ definitive hematopoietic cells in the aorta-gonad-mesonephros (AGM) region (no rescue of definitive hematopoiesis), whereas after exposure to tamoxifen at E7.5, a large population of CD45-positive cells are detected




Genotype
MGI:4420909
cn2
Allelic
Composition
Ascl1tm1And/Ascl1tm1And
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Ascl1-EGFP,-cre)1Jejo/0
Genetic
Background
involves: 129 * 129X1/SvJ * C57BL/6 * DBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ascl1tm1And mutation (1 available); any Ascl1 mutation (23 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Ascl1-EGFP,-cre)1Jejo mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• the precursors to dI3 and dI5 do not leave the ventricular zone at E10.5-E11.5 unlike in controls
• labeled cells do not appear to significantly contribute to the increase in dI2 and dI4 numbers




Genotype
MGI:5501188
cn3
Allelic
Composition
Nkx6-1tm1Jlr/Nkx6-1tm1.1Msan
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
Genetic
Background
involves: 129 * C57BL/6 * DBA * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Nkx6-1tm1.1Msan mutation (1 available); any Nkx6-1 mutation (3 available)
Nkx6-1tm1Jlr mutation (0 available); any Nkx6-1 mutation (3 available)
Tg(Ins2-cre)25Mgn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• maintenance of beta cell is impaired with conversion to delta cell fate

cellular
• maintenance of beta cell is impaired with conversion to delta cell fate




Genotype
MGI:5310800
cn4
Allelic
Composition
Rbpjtm1Hon/Rbpjtm1.1Hon
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ptf1atm2(cre/ESR1)Cvw/Ptf1a+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129S6/SvEvTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Ptf1atm2(cre/ESR1)Cvw mutation (3 available); any Ptf1a mutation (21 available)
Rbpjtm1.1Hon mutation (1 available); any Rbpj mutation (201 available)
Rbpjtm1Hon mutation (2 available); any Rbpj mutation (201 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
N
• tamoxifen-treated mice exhibit normal proliferation of YFP+ acinar cells




Genotype
MGI:5310799
cn5
Allelic
Composition
Rbpjtm1Hon/Rbpjtm1.1Hon
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hes1tm1(cre/ERT2)Lcm/Hes1+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Hes1tm1(cre/ERT2)Lcm mutation (0 available); any Hes1 mutation (14 available)
Rbpjtm1.1Hon mutation (1 available); any Rbpj mutation (201 available)
Rbpjtm1Hon mutation (2 available); any Rbpj mutation (201 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
N
• tamoxifen-treated mice exhibit normal pancreatic ductal morphology and pancreata mass
• tamoxifen-treated mice exhibit an increase in YFP+ acinar cells compared with control mice
• tamoxifen-treated mice exhibit a decrease in YFP+ centroacinar cells compared with control mice
• tamoxifen-treated mice exhibit a rapid transformation of YFP+ centroacinar cells into acinar cells compared with control mice
• however, tamoxifen-treated mice exhibit normal centroacinar and acinar cells proliferation and apoptosis

digestive/alimentary system
• tamoxifen-treated mice exhibit an increase in YFP+ acinar cells compared with control mice
• tamoxifen-treated mice exhibit a decrease in YFP+ centroacinar cells compared with control mice




Genotype
MGI:6377668
cn6
Allelic
Composition
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd9tm1c(EUCOMM)Hmgu mutation (0 available); any Cd9 mutation (100 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• as severe as in mice wild-type for Cd9

neoplasm
• at 8 weeks, more severe than in mice heterozygous for the Cd9 conditional allele

endocrine/exocrine glands
• at 8 weeks, more severe than in mice heterozygous for the Cd9 conditional allele




Genotype
MGI:6377669
cn7
Allelic
Composition
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd9tm1c(EUCOMM)Hmgu mutation (0 available); any Cd9 mutation (100 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• as severe as in mice wild-type for Cd9




Genotype
MGI:6377665
cn8
Allelic
Composition
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd9tm1c(EUCOMM)Hmgu mutation (0 available); any Cd9 mutation (100 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• not as severe as in mice wild-type for Cd9 or homozygous for a conditional allele




Genotype
MGI:6377664
cn9
Allelic
Composition
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd9tm1c(EUCOMM)Hmgu mutation (0 available); any Cd9 mutation (100 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• not as severe as in mice wild-type for Cd9 or homozygous for a conditional allele

neoplasm
• at 8 weeks, not as severe as in mice wild-type for Cd9 or homozygous for a conditional allele
• increased tumor weight compared to in mice homozygous for a conditional allele
• compared to in mice homozygous for a conditional allele

endocrine/exocrine glands
• at 8 weeks, not as severe as in mice wild-type for Cd9 or homozygous for a conditional allele
• increased tumor weight compared to in mice homozygous for a conditional allele




Genotype
MGI:6377672
cn10
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice die by 8 weeks of age




Genotype
MGI:6377671
cn11
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice die by 30 weeks of age

neoplasm

endocrine/exocrine glands




Genotype
MGI:6360589
cn12
Allelic
Composition
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Lyz2tm1(cre)Ifo mutation (13 available); any Lyz2 mutation (27 available)
Myo18atm1c(KOMP)Wtsi mutation (0 available); any Myo18a mutation (96 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• no differences in the morphological polarization, motility, or chemotactic efficiency of macrophages are seen in a complement C5a gradient chemotaxis assay
• macrophages exhibit normal Golgi morphology




Genotype
MGI:5762939
cn13
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Ighg1tm1(cre)Cgn mutation (3 available); any Ighg1 mutation (15 available)
Prdm1tm2Masu mutation (1 available); any Prdm1 mutation (48 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• hepatomegaly in one mouse
• splenomegaly in all terminally ill mice

hematopoietic system
• splenomegaly in all terminally ill mice
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization

immune system
• splenomegaly in all terminally ill mice
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
• occasional lymphadenopathy

liver/biliary system
• hepatomegaly in one mouse

mortality/aging
• shortened survival
• shortened survival

neoplasm
• spleens and lymph nodes show presence of large cells with a diffuse growth pattern, resembling diffuse large B cell lymphoma (DLBCL)
• lymphoproliferations are of clonal origin
• 5 of 6 DLBCLs are consistent with activated B cell-DLBCL




Genotype
MGI:5491493
cn14
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lhx6tm2Vpa/Lhx6tm2Vpa
Tg(Nkx2-1-cre)1Wdr/0
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Lhx6tm2Vpa mutation (0 available); any Lhx6 mutation (21 available)
Tg(Nkx2-1-cre)1Wdr mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• mice exhibit impaired somatostatin+ cortical interneuron differentiation compared with control mice




Genotype
MGI:5442608
cn15
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (9 available); any Cd19 mutation (36 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Rev3ltm1.1Diaz mutation (0 available); any Rev3l mutation (73 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• following with activation LPS, less so when activated with LPS plus IL4

immune system
N
• mice exhibit normal B cell development in the bone marrow and spleen
• following with activation LPS, less so when activated with LPS plus IL4
• following activated with LPS and IL4, mice exhibit decreased IgG1+ cells, indicating reduced class switch recombination, compared with wild-type mice
• following immunization with NP-CGG in alum, splenic B cells exhibit reduced mutation frequency in the rearranged Vh186.2 H chains compared with wild-type cells
• Peyer's patch B cells exhibit reduced accumulation of mutation at the intron downstream of rearranged V genes compared with wild-type cells

hematopoietic system
• following with activation LPS, less so when activated with LPS plus IL4
• following activated with LPS and IL4, mice exhibit decreased IgG1+ cells, indicating reduced class switch recombination, compared with wild-type mice
• following immunization with NP-CGG in alum, splenic B cells exhibit reduced mutation frequency in the rearranged Vh186.2 H chains compared with wild-type cells
• Peyer's patch B cells exhibit reduced accumulation of mutation at the intron downstream of rearranged V genes compared with wild-type cells




Genotype
MGI:5427870
cn16
Allelic
Composition
Cdc42tm1Brak/Cdc42tm1Brak
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdc42tm1Brak mutation (0 available); any Cdc42 mutation (42 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Lgr5tm1(cre/ERT2)Cle mutation (1 available); any Lgr5 mutation (26 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• intestinal crypt stem cells show increased cell death following tamoxifen administration
• 3 weeks after tamoxifen administration, mutant villus epithelial cells show disrupted cell polarity, as indicated by disorganized nuclear alignment
• stem cells contribute less to the villus epithelial compartments than in controls following tamoxifen administration
• 3 weeks after tamoxifen administration, more mutant stem cells in intestinal crypts undergo mitosis compared to control stem cells
• stem cells contribute less to the villus epithelial compartments than in controls following tamoxifen administration, indicating reduced clonal expansion of mutant stem cells
• 2 weeks after tamoxifen administration, mutant stem cells in intestinal crypts fail to give rise to Paneth cells
• 3 weeks after tamoxifen administration, mutant villus epithelial cells show disrupted cell polarity, as indicated by disorganized nuclear alignment

endocrine/exocrine glands
• 3 weeks after tamoxifen administration, more mutant stem cells in intestinal crypts undergo mitosis compared to control stem cells
• stem cells contribute less to the villus epithelial compartments than in controls following tamoxifen administration, indicating reduced clonal expansion of mutant stem cells
• 2 weeks after tamoxifen administration, mutant stem cells in intestinal crypts fail to give rise to Paneth cells

cellular
• intestinal crypt stem cells show increased cell death following tamoxifen administration




Genotype
MGI:4843965
cn17
Allelic
Composition
Lcp2tm1Gak/Lcp2tm2Gak
Tg(VAV1-cre)1Graf/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Lcp2tm1Gak mutation (1 available); any Lcp2 mutation (32 available)
Lcp2tm2Gak mutation (0 available); any Lcp2 mutation (32 available)
Tg(VAV1-cre)1Graf mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• at E14.5, mice exhibit blood-filled cutaneous lymphatics unlike in wild-type mice
• neonates exhibit blood-filled mesenteric lymphatics unlike in wild-type mice

digestive/alimentary system

homeostasis/metabolism




Genotype
MGI:4844099
cn18
Allelic
Composition
Syktm1.1(cre)Fkfr/Syktm1.1(cre)Fkfr
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Syktm1.1(cre)Fkfr mutation (0 available); any Syk mutation (31 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• fetal livers exhibit reduced leukocyte cellularity and colony forming cell frequency compared with wild-type livers
• at E12.5 and E15.5, abnormal blood vessel morphology is associated with massive leukocyte accumulation
• YFP+ monocyte- or macrophage-like cells accumulate in the skin compared to in Sykbtm1.1(cre)Fkfr/Sykb+ Gt(ROSA)26Sortm1(EYFP)Cos homozygotes

liver/biliary system
• at E13.5, liver development is reduced compared to in wild-type mice
• fetal livers exhibit reduced leukocyte cellularity and colony forming cell frequency compared with wild-type livers
• at E13.5

cardiovascular system
• at E12.5 and E15.5, abnormal blood vessel morphology is associated with massive leukocyte accumulation

hematopoietic system
• fetal livers exhibit reduced leukocyte cellularity and colony forming cell frequency compared with wild-type livers
• at E12.5 and E15.5, abnormal blood vessel morphology is associated with massive leukocyte accumulation
• YFP+ monocyte- or macrophage-like cells accumulate in the skin compared to in Sykbtm1.1(cre)Fkfr/Sykb+ Gt(ROSA)26Sortm1(EYFP)Cos homozygotes




Genotype
MGI:4410547
cn19
Allelic
Composition
Eedtm1Sho/Eedtm1Sho
Eportm1.1(EGFP/icre)Uk/Epor+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Eedtm1Sho mutation (1 available); any Eed mutation (112 available)
Eportm1.1(EGFP/icre)Uk mutation (2 available); any Epor mutation (18 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increase in the percentage of cells in the R2 stage (lin-,CD71+,Ter119-) and reduction in the percentage of cells in the R3 stage (lin-,CD71+,Ter119+)




Genotype
MGI:4843964
cn20
Allelic
Composition
Lcp2tm1Gak/Lcp2tm2Gak
Tg(Pf4-icre)Q3Rsko/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Lcp2tm1Gak mutation (1 available); any Lcp2 mutation (32 available)
Lcp2tm2Gak mutation (0 available); any Lcp2 mutation (32 available)
Tg(Pf4-icre)Q3Rsko mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• some mice exhibit blood-filled Peyer patches unlike in wild-type mice
• mice exhibit blood-filled mesenteric and intestinal lymphatic vessels unlike wild-type mice

homeostasis/metabolism
• platelets from neonates without vascular phenotypes exhibit intermediate levels of convulxin-stimulated fibrinogen binding compared with similarly treated wild-type cells

hematopoietic system
• platelets from neonates without vascular phenotypes exhibit intermediate levels of convulxin-stimulated fibrinogen binding compared with similarly treated wild-type cells




Genotype
MGI:3814191
cn21
Allelic
Composition
Ednrbtm1Nrd/Ednrbtm1Nrd
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ednrbtm1Nrd mutation (1 available); any Ednrb mutation (90 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
H2az2Tg(Wnt1-cre)11Rth mutation (2 available); any H2az2 mutation (25 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die 5 weeks after birth

growth/size/body

digestive/alimentary system

pigmentation
• mice lack coat pigment in the trunk

embryo
• enteric neural crest cells fail to reach the anus

integument
• mice lack coat pigment in the trunk

cellular
• enteric neural crest cells fail to reach the anus




Genotype
MGI:5009342
cn22
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ilktm1Star/Ilktm1Star
Tg(Krt1-15-cre/PGR*)22Cot/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Ilktm1Star mutation (1 available); any Ilk mutation (16 available)
Tg(Krt1-15-cre/PGR*)22Cot mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• during wound regeneration, RU486-treated mice exhibit YFP+ cells in the suprabasal layers but not the basal layers unlike in control mice
• in RU486-treated mice

integument
• following treatment with RU486, plated YFP+ hair follicle stem cells do not exhibit spreading unlike YFP- cells




Genotype
MGI:4837213
cn23
Allelic
Composition
Fevtm1Esd/Fevtm2Esd
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Fev-cre)1Esd/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fevtm1Esd mutation (0 available); any Fev mutation (11 available)
Fevtm2Esd mutation (0 available); any Fev mutation (11 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Fev-cre)1Esd mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• serotonergic innervation of the somatosensory cortex from dorsal raphe nucleus 5-HT neurons is significantly disrupted
• serotonergic innervation of the somatosensory cortex from dorsal raphe nucleus 5-HT neurons is significantly disrupted
• serotonergic innervation of the somatosensory cortex from dorsal raphe nucleus 5-HT neurons is significantly disrupted
• neither high nor low concentrations of 8-Hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) elicit a change in baseline currents in labeled 5HT neurons
• YFP+ cells show increased spontaneous firing of action potentials




Genotype
MGI:4844104
cn24
Allelic
Composition
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Corintm2(cre)Bamo/Corin+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Corintm2(cre)Bamo mutation (0 available); any Corin mutation (49 available)
Ctnnb1tm2.1Kem mutation (0 available); any Ctnnb1 mutation (41 available)
Ctnnb1tm2Kem mutation (1 available); any Ctnnb1 mutation (41 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• auchene growth is terminated before formation of the single bend unlike in wild-type mice
• however, the first segment is normal
• shorter, thinner, and more numerous than in wild-type mice
• at the end of the first hair cycle, all hairs are shorter and thinner than in wild-type mice
• the first segment of zigzag hairs is variable in length from 60% to 100% of wild-type hair length
• the second segment is reduced in length 50% to 60% compared to in wild-type mice
• the first and second segments are thinner than in wild-type mice
• zigzag hairs lack the third and fourth segment unlike in wild-type mice
• duration of anagen is decreased compared to in wild-type mice
• hair follicles enter catagen prematurely compared to in wild-type mice
• catagen onset occurs at P12 and is less synchronized than in wild-type mice
• telogen begins earlier than in wild-type mice
• 40 days after depilation, only sparse hair regenerate unlike in similarly treated wild-type mice
• proliferation of matrix progenitor cells abutting the dermal papilla (MPADs) and their progeny is reduced compared to in wild-type mice
• mice fail to exhibit normal hair follicle regeneration compared with wild-type mice
• the number of apoptotic cells averaged over all follicles is increased

cellular
• the number of apoptotic cells averaged over all follicles is increased




Genotype
MGI:5491188
cn25
Allelic
Composition
Hoxb1tm1.1Mist/Hoxb1tm1.1Mist
Tg(Hoxb1-cre)r4Mist/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Hoxb1tm1.1Mist mutation (1 available); any Hoxb1 mutation (18 available)
Tg(Hoxb1-cre)r4Mist mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hearing/vestibular/ear
• very few crossing medial olivocochlear (MOC) terminals are observed contacting outer hair cells in adult mice
• at P8, no difference in shape or organization of outer hair cells (OHCs) is observed at the apical and basal turns relative to wild-type, but in adults (3 months), OHC rows are severely disorganized with loss of some hair cells in the apical turn of the cochlea; no inner hair cells (IHCs) are lost
• OHCs in the basal turns show only slight abnormalities in ciliar organization and orientation
• at 3 months, threshold is elevated to 90 dB compared to the normal 40dB
• thresholds are elevated at all ages tested (from 1-12 months), increasing progressively to double the control level
• mice raised in acoustic isolation display ABR threshold increases compared to controls, indicating that sensitivity to environmental sounds is not a significant factor

nervous system
• at P8, no difference in shape or organization of outer hair cells (OHCs) is observed at the apical and basal turns relative to wild-type, but in adults (3 months), OHC rows are severely disorganized with loss of some hair cells in the apical turn of the cochlea; no inner hair cells (IHCs) are lost
• OHCs in the basal turns show only slight abnormalities in ciliar organization and orientation
• area of the ventral nucleus of the lateral lemniscus is severely reduced by about 90% compared to wild-type controls at P8
• specification and innervation of olivocochlear neurons is abnormal, no medial olivocochlear (MOC) efferent neurons cross the midline at P8
• the cholinergic population of lateral olivocochlear (LOC) neurons is very small indicating defective specification
• axon pathfinding defects are observed, with ectopic r4-derived projections crossing the midline and innervating the medial nucleus of the trapezoid body (MNTB)




Genotype
MGI:5491185
cn26
Allelic
Composition
Hoxb1tm1Mist/Hoxb1tm1Mist
Tg(Hoxb1-cre)r4Mist/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Hoxb1tm1Mist mutation (1 available); any Hoxb1 mutation (18 available)
Tg(Hoxb1-cre)r4Mist mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hearing/vestibular/ear
• very few crossing medial olivocochlear (MOC) terminals are observed contacting outer hair cells in adult mice
• at P8, no difference in shape or organization of outer hair cells (OHCs) is observed at the apical and basal turns relative to wild-type
• morphological defects of OHCs in adults are less severe than observed in constitutive Hoxb1-deficient (Hoxb1tm1.2Fmr) mice but statistically significant loss of OHCs and moderate OHC ciliar malformations are observed
• no abnormalities are observed in basal regions
• at 3 months, threshold is pathologically elevated compared to the normal 40dB, but not as significantly as in Hoxb1tm1.2Fmr (null) mice
• thresholds are elevated at all ages tested (from 1-12 months), increasing progressively to double the control level

nervous system
• at P8, no difference in shape or organization of outer hair cells (OHCs) is observed at the apical and basal turns relative to wild-type
• morphological defects of OHCs in adults are less severe than observed in constitutive Hoxb1-deficient (Hoxb1tm1.2Fmr) mice but statistically significant loss of OHCs and moderate OHC ciliar malformations are observed
• no abnormalities are observed in basal regions
• area of the ventral nucleus of the lateral lemniscus is reduced by about 50% compared to wild-type controls at P8
• specification and innervation of olivocochlear neurons is abnormal, no crossing olivocochlear (MOC) efferent neurons cross the midline at P8
• the cholinergic population of lateral olivocochlear (LOC) neurons is absent indicating defective specification
• axon pathfinding defects are observed, with ectopic r4-derived projections crossing the midline and innervating the medial nucleus of the trapezoid body (MNTB)




Genotype
MGI:5485201
cn27
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
Genetic
Background
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (141 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (28 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Mpz-cre)94Imeg mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• in of all doxycycline-treated mice arising from neural crest-lineage cells




Genotype
MGI:6360587
cn28
Allelic
Composition
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Tnnt2-cre)5Blh/0
Genetic
Background
involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * C57BL/6N * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Myo18atm1c(KOMP)Wtsi mutation (0 available); any Myo18a mutation (96 available)
Tg(Tnnt2-cre)5Blh mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• no mice are produced and only remnants of embryos are detected at E14.5




Genotype
MGI:5445987
cn29
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
S1pr1tm2Rlp/S1pr1tm2Rlp
Tg(Cdh5-cre/ERT2)1Rha/0
Genetic
Background
involves: 129S6/SvEvTac * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
S1pr1tm2Rlp mutation (2 available); any S1pr1 mutation (20 available)
Tg(Cdh5-cre/ERT2)1Rha mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• glomeruloid lesions form when tamoxifen is administered throughout pregnancy, although these lesions are less severe than in germ line null mice
• endothelial hyper-sprouting and retention of mural cell coverage on arteries and veins are detected after tamoxifen treatment

vision/eye
• endothelial hyper-sprouting and retention of mural cell coverage on arteries and veins are detected after tamoxifen treatment




Genotype
MGI:3830626
cn30
Allelic
Composition
Ctnnb1tm1Mmt/Ctnnb1+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Prom1tm1(cre/ERT2)Gilb/Prom1+
Genetic
Background
involves: 129S6/SvEvTac * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ctnnb1tm1Mmt mutation (0 available); any Ctnnb1 mutation (41 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Prom1tm1(cre/ERT2)Gilb mutation (1 available); any Prom1 mutation (44 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• two days after tamoxifen administration, there is a marked expansion of YFP+ cells within the crypts of the small intestine
• cultures of these cells yields four times as many, and much larger, clonogenic colonies
• ten days after tamoxifen administration, small intestine crypts are markedly disorganized with contiguous streams of YFP+ flowing out to the villi and forming a carpet of hyperplastic and grossly dysplastic cells
• sixty days after tamoxifen administration, the small intestine is twice the normal width and has a thickened, rugous appearance
• high-grade intraepithelial neoplasia and crypt adenoma formation is observed at the microscopic level sixty days after tamoxifen administration
• all mice die from the intestinal adenocarcinoma within 90 days of tamoxifen administration

mortality/aging
• tamoxifen administration leads to death of the mouse within 90 days from small intestine carcinoma

neoplasm
• two days after tamoxifen administration, there is a marked expansion of YFP+ cells within the crypts of the small intestine
• cultures of these cells yields four times as many, and much larger, clonogenic colonies
• ten days after tamoxifen administration, small intestine crypts are markedly disorganized with contiguous streams of YFP+ flowing out to the villi and forming a carpet of hyperplastic and grossly dysplastic cells
• sixty days after tamoxifen administration, the small intestine is twice the normal width and has a thickened, rugous appearance
• high-grade intraepithelial neoplasia and crypt adenoma formation is observed at the microscopic level sixty days after tamoxifen administration
• all mice die from the intestinal adenocarcinoma within 90 days of tamoxifen administration




Genotype
MGI:6827448
cn31
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
Pax7tm1(cre/ERT2)Gaka/Pax7tm1(cre/ERT2)Gaka
Paxbp1tm1.1Nju/Paxbp1tm1.1Nju
Genetic
Background
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6NCr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Pax7tm1(cre/ERT2)Gaka mutation (1 available); any Pax7 mutation (35 available)
Paxbp1tm1.1Nju mutation (0 available); any Paxbp1 mutation (32 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• fragmented mitochondria, largely restricted to perinuclear region, lacking interconnecting tubular network in activated muscle stem cells
• defective cellular respiration and glycolysis
• defective cellular respiration and glycolysis
• defective mitochondrial biogenesis in activated muscle stem cells
• defective cellular respiration and glycolysis

muscle
• virtual absence of regenerating myofibers 5 days after injection of cardiotoxin (CTX) into the tibialis anterior (TA) muscles and no muscle regeneration after 14 nor 30 days
• adipocyte infiltration 30 days after injection of cardiotoxin (CTX) into the tibialis anterior (TA) muscles




Genotype
MGI:5141116
cn32
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Resttm1.1Jhsi/Resttm1.1Jhsi
Tg(Nes-cre/ERT2)KEisc/0
Genetic
Background
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Resttm1.1Jhsi mutation (1 available); any Rest mutation (79 available)
Tg(Nes-cre/ERT2)KEisc mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• 20 days after tamoxifen treatment, mice exhibit a transient increase in hippocampal neurogenesis compared with control mice
• tamoxifen-treatment increased hippocampal neurogenesis in vitro and in vivo compared with controls
• tamoxifen-treated mice exhibit premature exit of quiescence compared with control mice
• tamoxifen-treated mice exhibit loss of neurogenic capacity of adult neurospheres and decreased neurogenesis over time compared with control mice
• neurospheres treated from tamoxifen-treated mice exhibit reduced self-renewal capacity compared with wild-type cells
• however, hippocampal neurogenesis is normal 10 and 30 days after tamoxifen treatment
• in tamoxifen-treated mice
• tamoxifen-treated mice exhibit decreased adult-generated immature and mature granule neurons compared with control mice

cellular
• 20 days after tamoxifen treatment, mice exhibit a transient increase in hippocampal neurogenesis compared with control mice
• tamoxifen-treatment increased hippocampal neurogenesis in vitro and in vivo compared with controls
• tamoxifen-treated mice exhibit premature exit of quiescence compared with control mice
• tamoxifen-treated mice exhibit loss of neurogenic capacity of adult neurospheres and decreased neurogenesis over time compared with control mice
• neurospheres treated from tamoxifen-treated mice exhibit reduced self-renewal capacity compared with wild-type cells
• however, hippocampal neurogenesis is normal 10 and 30 days after tamoxifen treatment
• in tamoxifen-treated mice




Genotype
MGI:5697630
cn33
Allelic
Composition
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw
Rag2tm1Fwa/Rag2tm1Fwa
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Pdpk1tm1.1Mlw mutation (0 available); any Pdpk1 mutation (129 available)
Rag2tm1Fwa mutation (46 available); any Rag2 mutation (93 available)
Tnfrsf4tm2(cre)Nik mutation (1 available); any Tnfrsf4 mutation (25 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice succumb to disease at 12-16 weeks of age

integument
• marker analysis indicates impaired keratinocyte differentiation
• mice develop mild skin dermatitis

immune system
• mice develop mild skin dermatitis

cellular
• marker analysis indicates impaired keratinocyte differentiation




Genotype
MGI:5502763
cn34
Allelic
Composition
Sh2d1atm1.1Knic/Sh2d1atm1.1Knic
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
Genetic
Background
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (5 available); any Ndor1 mutation (23 available)
Sh2d1atm1.1Knic mutation (0 available); any Sh2d1a mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• tamoxifen-treated mice exhibit normal invariant NKT cell numbers, phenotype and in vivo responsiveness to lipid antigens
• in vitro TCR-induced invariant NKT (iNKT) cell cytotoxicity from tamoxifen-treated mice is impaired compared to in control cells
• iNKT cells from tamoxifen-treated mice exhibit impaired control of tumor growth in vivo compared with control cells
• in response to EL4 targets, iNKT cells from tamoxifen-treated mcie form fewer conjugates and produce reduced levels of cytokines (IFN-gamma and IL4) compared with control cells
• however, iNKT cells exhibit normal trafficking to the tumor site
• from iNKT cells from tamoxifen-treated mice in response to EL4 targets
• from iNKT cells from tamoxifen-treated mice in response to EL4 targets

homeostasis/metabolism
• from iNKT cells from tamoxifen-treated mice in response to EL4 targets

hematopoietic system
• in vitro TCR-induced invariant NKT (iNKT) cell cytotoxicity from tamoxifen-treated mice is impaired compared to in control cells
• iNKT cells from tamoxifen-treated mice exhibit impaired control of tumor growth in vivo compared with control cells
• in response to EL4 targets, iNKT cells from tamoxifen-treated mcie form fewer conjugates and produce reduced levels of cytokines (IFN-gamma and IL4) compared with control cells
• however, iNKT cells exhibit normal trafficking to the tumor site




Genotype
MGI:5502766
cn35
Allelic
Composition
Sh2d1atm1.1Knic/Y
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
Genetic
Background
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (5 available); any Ndor1 mutation (23 available)
Sh2d1atm1.1Knic mutation (0 available); any Sh2d1a mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• tamoxifen-treated mice exhibit normal invariant NKT cell numbers, phenotype and in vivo responsiveness to lipid antigens
• in vitro TCR-induced invariant NKT (iNKT) cell cytotoxicity from tamoxifen-treated mice is impaired compared to in control cells
• iNKT cells from tamoxifen-treated mice exhibit impaired control of tumor growth in vivo compared with control cells
• in response to EL4 targets, iNKT cells from tamoxifen-treated mcie form fewer conjugates and produce reduced levels of cytokines (IFN-gamma and IL4) compared with control cells
• however, iNKT cells exhibit normal trafficking to the tumor site
• from iNKT cells from tamoxifen-treated mice in response to EL4 targets
• from iNKT cells from tamoxifen-treated mice in response to EL4 targets

homeostasis/metabolism
• from iNKT cells from tamoxifen-treated mice in response to EL4 targets

hematopoietic system
• in vitro TCR-induced invariant NKT (iNKT) cell cytotoxicity from tamoxifen-treated mice is impaired compared to in control cells
• iNKT cells from tamoxifen-treated mice exhibit impaired control of tumor growth in vivo compared with control cells
• in response to EL4 targets, iNKT cells from tamoxifen-treated mcie form fewer conjugates and produce reduced levels of cytokines (IFN-gamma and IL4) compared with control cells
• however, iNKT cells exhibit normal trafficking to the tumor site




Genotype
MGI:4879095
cn36
Allelic
Composition
Slc17a6tm1.1Thna/Slc17a6tm1.1Thna
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Slc6a3tm1(cre)Xz/Slc6a3+
Genetic
Background
involves: 129/Sv * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Slc17a6tm1.1Thna mutation (0 available); any Slc17a6 mutation (46 available)
Slc6a3tm1(cre)Xz mutation (2 available); any Slc6a3 mutation (53 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• only a minority of dopaminergic projections remain intake
• YFP+ dopamine neurons fail to exhibit glutamatergic excitatory postsynaptic currents (EPSCs) unlike control cells
• at P9 to P10, mice exhibit a reduction in glutamatergic with fewer neurons responding to ventral tegmental area stimulation compared with similarly treated control cells

behavior/neurological
• cocaine-treated mice exhibit less locomotor activity compared with control mice
• however, cocaine-treated mice exhibit conditioned place preference

homeostasis/metabolism
• the ventral striatum exhibit reduced dopamine and evoked dopamine release compared to in control mice




Genotype
MGI:4440935
cn37
Allelic
Composition
Bhlhe22tm3.1(cre)Meg/Bhlhe22tm1Meg
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bhlhe22tm1Meg mutation (0 available); any Bhlhe22 mutation (8 available)
Bhlhe22tm3.1(cre)Meg mutation (0 available); any Bhlhe22 mutation (8 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• quantification of neurons at P0 shows a 50% decrease in number of marked neurons in superficial dorsal horn compared to controls with no difference in numbers in any other spinal cord region
• significant increase in number of apoptotic cells (marked neurons) in superficial dorsal horn is observed at E18.5, but no difference is observed at E17.5 or 19.5
• partial loss of glutamatergic and GABAergic neurons is observed in dorsal horn
• number of marked neurons in dorsal horn are not different from controls when BrdU labeling is done at E12.5 or E13.5 and analysis is done at E17.5, indicating that neuronal mitosis is not affected




Genotype
MGI:3687456
cn38
Allelic
Composition
Cd79atm1(cre)Reth/Cd79a+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129X1/SvJ * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79atm1(cre)Reth mutation (3 available); any Cd79a mutation (20 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• 97% of B lineage cells are EYFP-positive compared with 33% in Cd19tm1(cre)Cgn-expressing mice indicating more efficient loxP recombination in developing B cells




Genotype
MGI:3696483
cn39
Allelic
Composition
Gt(ROSA)26Sortm1Hjf/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(CMV-cre)1Cgn/0
Genetic
Background
involves: 129X1/SvJ * BALB/cJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Gt(ROSA)26Sortm1Hjf mutation (4 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(CMV-cre)1Cgn mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• analysis of hematopoietic cells demonstrates reliable detection of YFP and RFP in same cells as well as in different cells




Genotype
MGI:5567830
cn40
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprttm1(Ins2-HBEGF)Herr/Y
Tg(Gcg-rtTA)#Herr/0
Tg(tetO-cre)1Jaw/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Hprttm1(Ins2-HBEGF)Herr mutation (0 available); any Hprt mutation (1274 available)
Tg(Gcg-rtTA)#Herr mutation (0 available)
Tg(tetO-cre)1Jaw mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• alpha cells in diphtheria-treated mice transdifferentiate into beta cells

cellular
• alpha cells in diphtheria-treated mice transdifferentiate into beta cells




Genotype
MGI:5697628
cn41
Allelic
Composition
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Pdpk1tm1.1Mlw mutation (0 available); any Pdpk1 mutation (129 available)
Tnfrsf4tm2(cre)Nik mutation (1 available); any Tnfrsf4 mutation (25 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice develop a wasting syndrome and succumb to disease by 11 weeks of age

growth/size/body
• mice develop an enlarged spleen

integument
• loss of hypodermal fat
• marker analysis indicates impaired keratinocyte differentiation
• mice with advanced disease show loss of skin barrier integrity at 7-8 weeks of age
• mice develop severe, systemic dermatitis starting at 5 weeks of age
• inflammation is not seen in the lung, liver, kidney or gut
• dermatitis is accompanied by hair loss
• loss of hair follicles
• mild epidermal hyperplasia and microabsceess are seen at 3 weeks of age but not at 10 days of age
• skin contains epidermal scales
• skin of mice with advanced disease contains lesions with epidermal damage, resulting in loss of skin barrier integrity
• dermatitis is accompanied by skin thickening
• increase in dermal fibrosis

immune system
• mice develop an enlarged spleen
• decrease in the frequency of Foxp3+ CD25+ Tregs with a corresponding increase in Foxp3-CD25+ effector T cells
• CD4 T cells exhibit an activated phenotype
• mice develop systemic T helper type 2 immunity
• mice develop peripheral lymphadenopathy
• mice develop severe, systemic dermatitis starting at 5 weeks of age
• inflammation is not seen in the lung, liver, kidney or gut

homeostasis/metabolism
• mice with advanced disease show loss of skin barrier integrity at 7-8 weeks of age

hematopoietic system
• mice develop an enlarged spleen
• decrease in the frequency of Foxp3+ CD25+ Tregs with a corresponding increase in Foxp3-CD25+ effector T cells
• CD4 T cells exhibit an activated phenotype
• mice develop systemic T helper type 2 immunity

cellular
• marker analysis indicates impaired keratinocyte differentiation

adipose tissue
• loss of hypodermal fat




Genotype
MGI:6723729
cn42
Allelic
Composition
Amotl1tm1Laho/Amotl1tm1Laho
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Cdh5-cre/ERT2)1Rha/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Amotl1tm1Laho mutation (0 available); any Amotl1 mutation (31 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Cdh5-cre/ERT2)1Rha mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• pups injected with tamoxifen at P1-P3 show abnormal pericyte morphology, with mural cells "bulging out" from blood vessels, in P6 retinas
• pups injected with tamoxifen at P1-P3 show a decreased density of the vessel network covering a smaller area of the retina at P6; the vascular density and number of branching points are significantly lower in the periphery and center of P6 retinas
• however, mice injected with tamoxifen at an adult stage show no alterations in the number of branching points and vascular density in adult retinas
• pups injected with tamoxifen at P1-P3 show a small but significant reduction in the number of tip cells per vessel length and abnormal pericyte morphology resulting in decreased pericyte coverage of blood vessels in P6 retinas
• however, the number of filopodia per tip cell is relatively normal at P6

vision/eye
• pups injected with tamoxifen at P1-P3 show a decreased density of the vessel network covering a smaller area of the retina at P6; the vascular density and number of branching points are significantly lower in the periphery and center of P6 retinas
• however, mice injected with tamoxifen at an adult stage show no alterations in the number of branching points and vascular density in adult retinas
• pups injected with tamoxifen at P1-P3 show a small but significant reduction in the number of tip cells per vessel length and abnormal pericyte morphology resulting in decreased pericyte coverage of blood vessels in P6 retinas
• however, the number of filopodia per tip cell is relatively normal at P6




Genotype
MGI:5548193
cn43
Allelic
Composition
Ctdnep1tm3Ryn/Ctdnep1tm3Ryn
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Six2tm1(tTA,tetO-EGFP/cre)Amc/Six2+
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ctdnep1tm3Ryn mutation (1 available); any Ctdnep1 mutation (16 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Six2tm1(tTA,tetO-EGFP/cre)Amc mutation (0 available); any Six2 mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• apoptotic cells in the nephron as early as P7

cellular
• apoptotic cells in the nephron as early as P7




Genotype
MGI:5567828
cn44
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprttm1(Ins2-HBEGF)Herr/Y
Tg(Ins2-cre/ERT)1Dam/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Hprttm1(Ins2-HBEGF)Herr mutation (0 available); any Hprt mutation (1274 available)
Tg(Ins2-cre/ERT)1Dam mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
N
• spared beta cells in diphtheria- and tamoxifen-treated mice do not exhibit increased replication
• bihormonal (glucagon+ and insulin+) cells arise in the islets of diphtheria-treated mice




Genotype
MGI:5564909
cn45
Allelic
Composition
Bcl11atm1Pwt/Bcl11atm1Pwt
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl11atm1Pwt mutation (0 available); any Bcl11a mutation (25 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• following pIpC induction cultured precursor cells fail to produce plasmacytoid dendritic cells

hematopoietic system
• following pIpC induction cultured precursor cells fail to produce plasmacytoid dendritic cells
• mild decrease in the total number of cells in GM-CSF-supplemented cultures following pIpC treatment
• following pIpC induction cultured precursor cells fail to produce plasmacytoid dendritic cells and in vivo
• in Flt3L-supplemented cultures following pIpC induced deletion in hematopoietic stem cells and in vivo

immune system
• following pIpC induction cultured precursor cells fail to produce plasmacytoid dendritic cells
• mild decrease in the total number of cells in GM-CSF-supplemented cultures following pIpC treatment
• following pIpC induction cultured precursor cells fail to produce plasmacytoid dendritic cells and in vivo
• in Flt3L-supplemented cultures following pIpC induced deletion in hematopoietic stem cells and in vivo




Genotype
MGI:3831109
cn46
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/?
Tg(Il17f-cre)1Awai/?
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * DBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Il17f-cre)1Awai mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype




Genotype
MGI:4437914
cn47
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Plcg1tm1Gcrp/Plcg1tm1Rwen
Tg(Cd4-cre)1Cwi/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Plcg1tm1Gcrp mutation (0 available); any Plcg1 mutation (27 available)
Plcg1tm1Rwen mutation (0 available); any Plcg1 mutation (27 available)
Tg(Cd4-cre)1Cwi mutation (8 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• following reactivation
• differentiation into CD4 or CD8 single positive thymocytes is reduced compared to in wild-type mice
• differentiation into CD4 or CD8 single positive thymocytes is reduced compared to in wild-type mice
• peripheral T cells are reduced compared to in wild-type mice
• in transplantation experiments, T cells are less competitive than wild-type T cells
• CD4+ thymocytes are more profoundly decreased than CD8+ thymocytes
• mice exhibit an increase in T cell activation compared with wild-type mice
• however, activation phenotype is not cell intrinsic
• in response to stimulation with anti-CD3m anti-CD3/anti-CD28, or anti-CD3/IL2, T cell proliferation is reduced compared to in similarly treated Plcg1tm1Gcrp/Plcg1+ Tg(CD4-cre)1Cwi Gt(ROSA)26Sortm1(EYFP)Cos mice
• however, treatment with PMA/ionomycin restores proliferation
• YFP+ T regulatory cells exhibit reduced ability to suppress naive T cell proliferation compared with wild-type T cells
• following anti-CD3/anti-CD28 stimulation, slightly fewer IFN-gamma producing single positive T cells are detected compared to in similarly treated Plcg1tm1Gcrp/Plcg1+ Tg(CD4-cre)1Cwi Gt(ROSA)26Sortm1(EYFP)Cos mice
• following anti-CD3/anti-CD28 stimulation, IL2 production by single positive T cells is reduced compared to in similarly treated Plcg1tm1Gcrp/Plcg1+ Tg(CD4-cre)1Cwi Gt(ROSA)26Sortm1(EYFP)Cos mice
• mice exhibit dermatitis unlike wild-type mice
• however, treatment with wild-type T regulatory cells prevents development of symptom

growth/size/body
• mice weight less than wild-type mice
• however, transfer of regulatory T cells restores normal weight gain

digestive/alimentary system
• mice exhibit rectal prolapse unlike wild-type mice
• however, treatment with wild-type T regulatory cells prevents development of symptom

hematopoietic system
• following reactivation
• differentiation into CD4 or CD8 single positive thymocytes is reduced compared to in wild-type mice
• differentiation into CD4 or CD8 single positive thymocytes is reduced compared to in wild-type mice
• peripheral T cells are reduced compared to in wild-type mice
• in transplantation experiments, T cells are less competitive than wild-type T cells
• CD4+ thymocytes are more profoundly decreased than CD8+ thymocytes
• mice exhibit an increase in T cell activation compared with wild-type mice
• however, activation phenotype is not cell intrinsic
• in response to stimulation with anti-CD3m anti-CD3/anti-CD28, or anti-CD3/IL2, T cell proliferation is reduced compared to in similarly treated Plcg1tm1Gcrp/Plcg1+ Tg(CD4-cre)1Cwi Gt(ROSA)26Sortm1(EYFP)Cos mice
• however, treatment with PMA/ionomycin restores proliferation
• YFP+ T regulatory cells exhibit reduced ability to suppress naive T cell proliferation compared with wild-type T cells

integument
• mice exhibit dermatitis unlike wild-type mice
• however, treatment with wild-type T regulatory cells prevents development of symptom
• mice exhibit alopecia unlike wild-type mice
• however, treatment with wild-type T regulatory cells prevents development of symptom

cellular
• following reactivation
• in response to stimulation with anti-CD3m anti-CD3/anti-CD28, or anti-CD3/IL2, T cell proliferation is reduced compared to in similarly treated Plcg1tm1Gcrp/Plcg1+ Tg(CD4-cre)1Cwi Gt(ROSA)26Sortm1(EYFP)Cos mice
• however, treatment with PMA/ionomycin restores proliferation




Genotype
MGI:5634193
cn48
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Il22tm1.1(icre)Stck/Il22+
Genetic
Background
involves: 129X1/SvJ * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Il22tm1.1(icre)Stck mutation (1 available); any Il22 mutation (19 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• mice infected with Citrobacter exhibit increased transient weight loss compared with wild-type mice and mice heterozygous for a knock-out allele
• however, mice exhibit normal clearance and kinetics of infection

growth/size/body
• mice infected with Citrobacter exhibit increased transient weight loss compared with wild-type mice and mice heterozygous for a knock-out allele
• however, mice exhibit normal clearance and kinetics of infection




Genotype
MGI:3696478
cn49
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/?
Tg(Lck-cre)548Jxm/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Lck-cre)548Jxm mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mice are viable; strong variation in percentage of RFP-positive T lymphocytes is observed between individual mice, as well as activation in non-T lineage cells




Genotype
MGI:3835668
cn50
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Plp1-Ncre)DFki/0
Tg(Plp1-Ccre)RFki/0
Genetic
Background
involves: 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(Plp1-Ccre)RFki mutation (0 available)
Tg(Plp1-Ncre)DFki mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype




Genotype
MGI:3835669
cn51
Allelic
Composition
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(GFAP-Ccre)FFki/0
Tg(GFAP-Ncre)VFki/0
Genetic
Background
involves: 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(EYFP)Cos mutation (9 available); any Gt(ROSA)26Sor mutation (745 available)
Tg(GFAP-Ccre)FFki mutation (0 available)
Tg(GFAP-Ncre)VFki mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
01/12/2022
MGI 6.17
The Jackson Laboratory